Durability of Integrase Strand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort

Emanuele Focà1, Andrea Calcagno2, Stefano Calza3,4, Stefano Renzetti3,4, Annacarla Chiesa1,*, Matteo Siano5, Giuseppe De Socio6, Stefania Piconi7, Giancarlo Orofino8, Giordano Madeddu9, Anna Maria Cattelan10, Silvia Nozza11, Micol Ferrara2, Jovana Milic12, Benedetto Maurizio Celesia13, Francesco Castelli1, Giovanni Guaraldi12

1 Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy, 2 Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy, 3 Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy, 4 BDbiomed lab, University of Brescia, Brescia, Italy, 5 3rd Division of Infectious Diseases, University of Milano, L. Sacco Hospital, Milano, Italy, 6 Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy, 7 1st Division of Infectious Diseases Unit, University of Milano, L. Sacco Hospital, Milano, Italy, 8 Unit of Infectious Diseases, ‘Divisione A’, Amedeo di Savoia Hospital, ASLTO2, Torino, Italy, 9 Unit of Infectious and Tropical Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy, 10 Unit of Infectious Diseases, Department of Internal Medicine, Azienda Ospedaliero-Universitaria di Padova, Padova, Italy, 11 Department of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy, 12 Department of Mother, Child and Adult Medicine and Surgical Science, Infectious Disease Clinic, University of Modena and Reggio Emilia, Modena, Italy, 13 Division of Infectious Diseases, Department of Clinical and Molecular Biomedicine, University of Catania, ARNAS Garibaldi, Catania, Italy

* annacarla.chiesa@gmail.com

Abstract

Objective

To investigate the durability of the first integrase inhibitor-based regimen in a HIV geriatric multicentric prospective cohort and to explore the reasons of regimen discontinuation.

Design

This is an analysis conducted on the Geriatric Patients Living with HIV/AIDS (GEPO) cohort, an Italian prospective observational multicentre cohort of people living with HIV with 65 years of age or more.

Methods

The analysis was performed using R (version 4.0.2). The tests performed were two sided assuming a 5% significance level (Kruskal-Wallis test, Chi-squared test, log-rank test and a Cox Proportional Hazard model). The proportion of participants discontinuing the three regimens was displayed using cumulative curves.
Among 1531 patients enrolled between 2017 and 2019 in the GEPPO cohort, we included 822 participants in this analysis. At baseline, median age was 69.8, the immunovirological profile good, multimorbidity was present in 42.3% of participants, while 27.4% were on poly-pharmacy. Overall, 483, 243 and 96 participants received DTG, RAL and EVG/c respectively as first InSTI. At the end of the follow up 6.4%, 21.1% and 22.9% participants discontinued DTG, RAL and EVG/c respectively. Using a log-rank test, EVG showed a significantly lower durability than DTG (p < 0.001) or RAL (p 0.05) or both, DTG and RAL (p < 0.001). Among participants who discontinued their regimen we found 0 virological failures and 56.7% simplification/deprescription.

Conclusions
The three integrase inhibitors considered showed a good durability and no virological failures in geriatric patients such as those enrolled in the GEPPO cohort when used in a two or three drug regimen.

Introduction
People living with HIV (PLWH) are aging, mainly for the longer life expectancy under effective combined antiretroviral therapy (cART) and the increasing age of newly diagnosed patients [1, 2]. Geriatric populations (conventionally considered as people with 65 or more years of age) present a peculiar pattern of health necessity. An integrated management is therefore needed to guarantee a healthy aging because PLWH have a higher risk of age-associated events compared with the same non-HIV age cohorts [3]. For this reason a specific focus on elderly PLWH is being implemented in several guidelines [4, 5].

Multimorbidity (i.e. the presence of at least 3 co-morbidities) is often present in elderly PLWH and it is reported along with polypharmacy (i.e. the concomitant intake of at least 5 non-antiretroviral medications); both conditions have been associated with worse outcomes [2, 6].

Moreover, there is a lack of randomized controlled trials (RCTs) designed properly to investigate efficacy and toxicity of antiretrovirals in geriatric patients living with HIV. Recently some sub-studies of RCTs including a ≥65 years old sub-group analysis were presented and only one non-randomized single arm clinical trial showing good tolerability, safety profile and immunovirological response with InSTI-based cART in geriatric PLWH both for cART experienced and naïve patients [7, 8].

One of the methods that may empirically show the tolerability of a drug regimen is its durability. Durability, defined as the time to regimen modification, depends on major outcomes (e.g. allergic reactions, virological failure or drug-drug interactions) as well as on more subtle factors such as mild side effects, the impact on quality of life, polypharmacy, comorbidities and patients’ and physicians’ choice [9]. Integrase Strand Transfer Inhibitor (InSTI) containing regimens are the preferred treatment in naïve patients by several international guidelines: the class includes raltegravir (RAL), elvitegravir/cobicistat (EVG/c), dolutegravir (DTG) and bictegravir (BIC, only recently added to the armamentarium with very limited real-life data) [4]. To date, no studies investigated the durability of InSTIs in geriatric PLWH. Therefore, in
order to contribute filling the gap in current knowledge, we aimed to explore the durability of InSTI-based regimens in a geriatric cohort of PLWH.

**Methods**

Participants were prospectively recruited between 2017 and 2019 from the Geriatric Patients Living with HIV/AIDS (GEppo) cohort, an Italian prospective observational multicentre study characterising multimorbidity and geriatric syndromes in PLWH aged ≥65 years with a special focus on cART prescription. Participants are followed according to clinical practice and data about geriatric outcomes are recorded once a year. Regarding this study, inclusion criteria was the initiation of first InSTI-based regimen after 2017. InSTIs included in the analysis were DTG, RAL and EVG/c. Moreover, we explored the presence of multi-morbidity and polypharmacy: those conditions have been previously defined and described in the GEppo cohort by Nozza et al [10].

Study primary endpoint was InSTI durability defined as time to discontinuation of first InSTI regimen; we also analyzed the reason for cART discontinuation, categorized as: 1) virological failure, 2) simplification/deprescription, 3) others (including toxicity).

**Statistical analysis**

Continuous variables were described using median and interquartile range (IQR) while categorical variables were described with absolute frequencies and percentages. Comparisons of continuous variables among InSTI regimes were performed using Kruskal-Wallis test while Chi-squared test was used for categorical variables. The difference of InSTI discontinuation, considered as the first regimen shift and modelled as a time-to-event variable, was tested through a log-rank test and a Cox Proportional Hazard model adjusting by age, sex, multimorbidity (defined as the presence of at least 3 comorbidities) and the use of abacavir. The same analysis was conducted for the subgroup on InSTI dual regimen. Median survival is defined as the time needed for half of the participants in each regimen to discontinue the treatment. The proportion of participants discontinuing the three regimens was displayed using cumulative curves. All the test performed were two sided assuming a 5% significance level. All analyses were performed using R (version 4.0.2).

**Ethics statement**

This study belongs to the GEppo project. This project obtained approval by the Research Ethics Board of each individual institute belonging to the GEppo cohort. The Research Ethics Board of the coordinating centre is the "Comitato Etico di Brescia”. All data were fully anonymized before the statistical analysis was performed. Written informed consent was asked at the first useful access.

**Results**

Among 1531 patients aged ≥65 years followed in the GEppo cohort, we included 822 participants in this analysis. At baseline (defined as the time of inclusion in the analysis) median age was 69.8 (IQR 7.4). Among study participants, 666 (81%) were males, the median CD4+ T-cell count at baseline was 618 cell/μl (IQR 25–75: 437.5–814.0), and 95.2% had HIV RNA <50 copies/ml. Multimorbidity was present in 356 (43.3%) participants, while 225 (27.4%) were on polypharmacy (all summary statistics are reported in Table 1).

Overall, 483, 243 and 96 participants received DTG, RAL and EVG/c respectively as first InSTI. At the baseline, participants were on cART from a median (IQR 25–75) of 16.1 (10.3–
### Table 1. Overall and divided by first InSTI groups summary statistics of the variables considered in the study: Median and interquartile range are shown for continuous variables while counts and percentages are considered for categorical variables. Kruskal-Wallis test and Chi-squared test were used for continuous and categorical variables respectively.

| Variable                                      | DTG (N = 483) | EVG (N = 96) | RAL (N = 243) | Total (N = 822) | p value |
|-----------------------------------------------|---------------|--------------|---------------|-----------------|---------|
| **Age (years)**                               |               |              |               |                 |         |
| Median (Q1, Q3)                               | 69.8 (67.0, 74.4) | 69.0 (66.3, 71.6) | 70.6 (67.3, 75.6) | 69.8 (67.0, 74.4) | 0.020   |
| **Sex**                                       |               |              |               |                 | 0.645   |
| Female                                        | 88 (18.2%)    | 15 (15.6%)   | 52 (21.4%)    | 155 (18.9%)     |         |
| Male                                          | 394 (81.6%)   | 81 (84.4%)   | 191 (78.6%)   | 666 (81.0%)     |         |
| Transgender                                   | 1 (0.2%)      | 0 (0.0%)     | 0 (0.0%)      | 1 (0.1%)        |         |
| **Multi-Morbidities (at least 3 comorbidities)** |          |              |               |                 | 0.014   |
| No                                            | 284 (58.8%)   | 62 (64.6%)   | 120 (49.4%)   | 466 (56.7%)     |         |
| Yes                                           | 199 (41.2%)   | 34 (35.4%)   | 123 (50.6%)   | 356 (43.3%)     |         |
| **Polypharmacy (>5 medications)**             |               |              |               |                 | < 0.001 |
| • No                                          | 367 (76.0%)   | 78 (81.2%)   | 152 (62.6%)   | 597 (72.6%)     |         |
| • Yes                                         | 116 (24.0%)   | 18 (18.8%)   | 91 (37.4%)    | 225 (27.4%)     |         |
| **HAART duration (years)**                    |               |              |               |                 | 0.001   |
| Median (Q1, Q3)                               | 16.1 (10.3, 20.4) | 13.5 (8.5, 19.9) | 18.3 (12.0, 21.1) | 16.4 (10.2, 20.7) |         |
| **CD4**                                       |               |              |               |                 | 0.401   |
| Median (Q1, Q3)                               | 610.0 (443.0, 826.0) | 651.0 (435.5, 835.8) | 618.0 (440.8, 733.8) | 618.0 (437.5, 814.0) |         |
| **HIV suppressed (not detectable or RNA < 50)**|               |              |               |                 | 0.125   |
| • No                                          | 13 (4.6%)     | 5 (10.4%)    | 3 (2.9%)      | 21 (4.8%)       |         |
| • Yes                                         | 268 (95.4%)   | 43 (89.6%)   | 102 (97.1%)   | 413 (95.2%)     |         |
| **DUAL (InSTI + other)**                      |               |              |               |                 | < 0.001 |
| • No                                          | 424 (87.8%)   | NA           | 189 (77.8%)   | 709 (86.3%)     |         |
| • Yes                                         | 59 (12.2%)    | NA           | 54 (22.2%)    | 113 (13.7%)     |         |
| **DUAL (InSTI + Lamivudine)**                 |               |              |               |                 | < 0.001 |
| • No                                          | 394 (81.6%)   | NA           | 242 (99.6%)   | 732 (89.1%)     |         |
| • Yes                                         | 89 (18.4%)    | NA           | 1 (0.4%)      | 90 (10.9%)      |         |
| **DUAL (InSTI + Rilpivirine)**                |               |              |               |                 | < 0.001 |
| • No                                          | 436 (90.3%)   | NA           | 240 (98.8%)   | 772 (93.9%)     |         |
| • Yes                                         | 47 (9.7%)     | NA           | 3 (1.2%)      | 50 (6.1%)       |         |
| **TRIPLE (InSTI + 2 others)**                 |               |              |               |                 | < 0.001 |
| • No                                          | 207 (42.9%)   | 5 (5.2%)     | 84 (34.6%)    | 296 (36.0%)     |         |
| • Yes                                         | 276 (57.1%)   | 91 (94.8%)   | 159 (65.4%)   | 526 (64.0%)     |         |
| **MEGA (InSTI + at least 4 others)—molecules**|          |              |               |                 | < 0.001 |
| • No                                          | 471 (97.5%)   | 91 (94.8%)   | 217 (89.3%)   | 779 (94.8%)     |         |
| • Yes                                         | 12 (2.5%)     | 5 (5.2%)     | 26 (10.7%)    | 43 (5.2%)       |         |
| **Abacavir**                                  |               |              |               |                 | < 0.001 |
| • No                                          | 325 (67.3%)   | 96 (100.0%)  | 216 (88.9%)   | 637 (77.5%)     |         |
| • Yes                                         | 158 (32.7%)   | 0 (0.0%)     | 27 (11.1%)    | 185 (22.5%)     |         |
| **Single Tablet Regimen**                     |               |              |               |                 | < 0.001 |
| • No                                          | 330 (68.3%)   | 5 (5.2%)     | 243 (100.0%)  | 578 (70.3%)     |         |
| • Yes                                         | 153 (31.7%)   | 91 (94.8%)   | 0 (0.0%)      | 244 (29.7%)     |         |

NA: not applicable.

https://doi.org/10.1371/journal.pone.0258533.1001
20.4), 18.3 (12.0–21.1) and 13.5 (8.5–19.9) years in the DTG, RAL and EVG/c group respectively, with significant differences among the three InSTIs (Kruskal-Wallis test, p = 0.001).

The median follow-up time, computed with KM estimator, was 12.7 months. At the end of the follow-up 29 (6.0%), 52 (21.4%) and 22 (22.9%) participants discontinued DTG, RAL and EVG/c respectively. The median discontinuation time calculated as the time required to reach a drug discontinuation of 50% was 29 months for EVG and 36 months for RAL while DTG did not reach 50% discontinuation (after 36 months the proportion of participants who discontinued DTG was 23%). Using a log-rank test, EVG showed a significantly lower durability than DTG (p < 0.001) or RAL (p = 0.048) or both DTG and RAL (p < 0.001). The curves showing the proportion of participants discontinuing InSTI regimen are shown in Fig 1A. When adjusting for age, sex, multimorbidity and abacavir usage we were still able to find a significant difference between DTG and EVG but not between RAL and EVG (p = 0.002 and p = 0.111 respectively, Table 2).

An intriguing treatment option recently implemented thanks to several RCTs, are two drug regimens (2DR) InSTI-based. Analyzing this treatment choice, we found that overall 526 (64.0%) of the participants received a standard triple therapy while 195 (40.4%) received DTG-based 2DR and 58 RAL-based 2DR. Among those receiving DTG-based 2DR, for 89 (45.6%) the second drug was lamivudine (3TC), for 47 (24.1%) rilpivirine (RPV), and for 59 (30.3%) other agents. Durability of InSTI-based 2DR is shown in Fig 1B (EVG/c is not included because it is available in 3DR regimen only).

Among participants who discontinued their regimen (103) we found 0 (0%) virological failure, 59 (56.7%) simplification/deprescription, 11 (25.9%) other reasons, including 4 adverse events and 1 participant’s preference. For the remaining 33 participants, data regarding the reason of InSTI discontinuation are missing, although among them 4 participants changed molecules in the InSTI class.

**Discussion**

This longitudinal study in geriatric PLWH demonstrated a good durability of InSTI-based regimens analysed with a particularly good performance of DTG-based regimens (regardless of accompanying drugs).

Geriatric Patients Living with HIV/AIDS (GEPO) is a prospective observational cohort including consecutive HIV-positive geriatric patients in care at 11 HIV clinics all over Italy compared with a HIV-negative control group. The aim is monitoring the health status of geriatric PLWH as well as study how the common geriatric care model applies to PLWH [11].

The 822 participants at GEPO cohort also enrolled in this study were long standing cART experienced with a median history of more than 10 years of antiretroviral drugs and presenting a good immunovirological profile. Aging is usually associated with a higher tendency to treatment adherence [2] which may explain their good immunovirological profile. However, a recent report from GEPO Cohort showed that only the 31% experienced a normalization of immunological profile with a significant difference between genders [12, 13].

As expected, in a cohort of people with a median age of 70 years, multimorbidity and poly-pharmacy were common findings (42 and 27%, respectively). It is well known that these two factors should be carefully considered when choosing an ART regimen: if virological suppression is achieved, NRTI-sparing, unboosted regimens are emerging as intriguing treatment options as well as the possibility to simplify to dual therapy should be considered [2]. Notably, tenofovir alafenamide should be preferred to tenofovir dipropyl fumarate due to lower toxicity on bone mineral density and renal function [2]. Moreover, in our cohort Guaraldi et al. did
Fig 1. Curves showing the proportion of subjects discontinuing the InSTI regime. Comparison performed using log-rank test for the whole cohort—p < 0.0001—(A), and the subgroup of patients undergoing a dual drug regimen (B).

https://doi.org/10.1371/journal.pone.0258533.g001
not observe a weight gain in participant switching from tenofovir diproxil fumarate to tenofovir alafenamide nor from an INSTI-free cART to a DTG-based regimen [14].

The emerging interest on DTG-based 2DR has been extensively investigated in RCTs when DTG was combined/co-formulated with RPV or 3TC [15]. These regimens, beyond virological durability harbor pharmacokinetic benefits of low burden of DDI and single tablet regimen (STR) convenience.

These data are confirmed in our cohort. None of the participants discontinued due to virological failure, while 56.7% for simplification/deprescription, and 25.9% for toxicity. These data are in line with what found by Eaton et al. [9]: ART changes due to virological failure are less and less common in recent years while most switches are due to convenience and side effects. Moreover, the low rate of transmitted resistance-associated mutations to INSTIs and the high genetic barrier of this class contributes explaining this result [16].

These data may also be put in the perspective of the fourth 90% target recently suggested as outcome in the HIV treatment cascade. Switching ARV in geriatric PLWH is mainly driven by a proactive strategy to avoid polypharmacy in a de-prescribing approach, often applied in general geriatric population [17]. In this context, given the long durability of the prescribed regimen, this study contributes to generate new data regarding safety of both 3DR and 2DR INSTI based regimen in this particular population.

EVL and RAL also showed a good durability (29 and 36 months respectively), though they were less preferred in GEPPO cohort in comparison to DTG. A few hypotheses may be provided. EVL is necessarily boosted with cobicistat which strongly inhibit CYP3A4 displaying a higher EVL risk of DDIs, producing concerns in the context of polypharmacy. RAL discontinuation may be due to high pill burden regardless of the once a day RAL formulation which has been recently released. To note RAL anyway showed a good durability, higher than EVL.

In geriatric PLWH deprescription options should be the standard of care. This process implies therapy review with the goal of medication reconciliation and medication prioritizations to prevent unnecessary drug prescriptions. In this context 2DR and 3DR unboosted STR regimens should be prioritised [18]. Recent data on STR bictegravir-based treatments in elderly participants showed excellent efficacy and tolerability: the randomized clinical setting support further real-life investigations [7].

Several limitations of our study should be acknowledged: missing data, short follow up, only one time-point per year, and the observational design, unable sometimes to evaluate the clinical decisions.

**Conclusion**

Although the three INSTI considered showed some differences in this geriatric cohort of patients, all of them had a durability of more than two years with no virological failures. In

| Predictors | Estimates | CI      | p     |
|------------|-----------|---------|-------|
| InSTI: DTG vs EVG | 0.24 | 0.09–0.59 | 0.002 |
| InSTI: RAL vs EVG | 0.43 | 0.15–1.21 | 0.111 |
| Age | 1.00 | 0.97–1.04 | 0.920 |
| Sex: Male vs Female | 1.11 | 0.68–1.82 | 0.663 |
| Multimorbidity: Yes vs No | 0.67 | 0.44–1.02 | 0.064 |
| Abacavir: Yes vs No | 0.85 | 0.41–1.75 | 0.658 |
| STR: Yes vs No | 0.63 | 0.25–1.57 | 0.319 |

https://doi.org/10.1371/journal.pone.0258533.t002
geriatric patients such as those enrolled in the GEPP0 cohort 2DR and 3DR unboosted STR regimens are favoured and display long term durability.

Supporting information
S1 Data. (XLSX)

Author Contributions

Conceptualization: Emanuele Focà, Andrea Calcagno, Giuseppe De Socio.

Formal analysis: Stefano Calza, Stefano Renzetti.

Investigation: Emanuele Focà.

Methodology: Emanuele Focà.

Project administration: Emanuele Focà.

Supervision: Emanuele Focà.

Writing – original draft: Annacarla Chiesa.

Writing – review & editing: Emanuele Focà, Andrea Calcagno, Stefano Calza, Stefano Renzetti, Matteo Siano, Giuseppe De Socio, Stefania Piconi, Giancarlo Orofino, Giordano Madeddu, Anna Maria Cattelan, Silvia Nozza, Micol Ferrara, Jovana Milic, Benedetto Maurizio Celesia, Francesco Castelli, Giovanni Guaraldi.

References

1. Tavoschi L. et al., “New HIV diagnoses among adults aged 50 years or older in 31 European countries, 2004–15: an analysis of surveillance data,” Lancet HIV, vol. 4, no. 11, pp. e514–e521, 2017, https://doi.org/10.1016/S2352-3018(17)30155-8 PMID: 28967582

2. Guaraldi G. et al., “The Management of Geriatric and Frail HIV Patients. A 2017 Update from the Italian Guidelines for the Use of Antiretroviral Agents and the Diagnostic Clinical Management of HIV-1 Infected Persons,” J. frailty aging, vol. 8, no. 1, pp. 10–16, Jan. 2019, https://doi.org/10.14283/jfa.2018.42 PMID: 30734825

3. Milic J., Russwurm M., Cerezales Calvino A., Brañas F., Sánchez-Conde M., and Guaraldi G., “European cohorts of older HIV adults: POPPY, AGEhIV, GEPP0, COBRA and FUNCFRAIL,” Eur. Geriatr. Med., vol. 10, no. 2, pp. 247–257, 2019, https://doi.org/10.1007/s41999-019-00170-8

4. EACS, “European AIDS Clinical Society Guidelines, version 10.1. October 2020.”

5. Department of Health and Human Services, “Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV,” 2018. [Online]. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. [Accessed: 08-Jul-2020].

6. Società Italiana di Malattie Infettive e Tropicali, Linee Guida Italiane sull’utilizzo della Terapia Antiretrovirale e la gestione diagnostico-clinica delle persone con infezione da HIV-1. 2017.

7. Maggioio F. et al., “Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged > 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial,” Infect. Dis. Ther., 2021, https://doi.org/10.1007/s40121-021-00419-5 PMID: 33666573

8. Spinelli F. et al., “Dolutegravir-based regimens in treatment-naïve and treatment-experienced populations: analyses of 6 phase III clinical trials,” HIV Res. Clin. Pract., pp. 1–9, 2021, https://doi.org/10.1080/25787489.2021.1941672 PMID: 34180785

9. Eaton E. F. et al., “Trends in antiretroviral therapy prescription, durability and modification: New drugs, more changes, but less failure,” AIDS, vol. 32, no. 3, pp. 347–355, Jan. 2018, https://doi.org/10.1097/QAD.0000000000001708 PMID: 29194118

10. Nozza S. et al., “Antiretroviral therapy in geriatric HIV patients: The GEPP0 cohort study,” J. Antimicrob. Chemother., vol. 72, no. 10, pp. 2879–2886, 2017, https://doi.org/10.1093/jac/dkx169 PMID: 28605493
11. Guaraldi G. et al., “The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: A cross sectional study of people aged 65–74 years and more than 75 years,” *BMC Geriatr.*, vol. 18, no. 99, Apr. 2018, https://doi.org/10.1186/s12877-018-0789-0 PMID: 29678160

12. Focà E. et al., “Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian ‘GEPPO’ Cohort,” *PLoS One*, vol. 14, no. 10, p. e0222225, 2019, https://doi.org/10.1371/journal.pone.0222225 PMID: 31622347

13. Calcagno A. et al., “Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-Infected Patients,” *J. Acquir. Immune Defic. Syndr.*, vol. 76, no. 3, pp. 338–342, 2017, https://doi.org/10.1097/QAI.0000000000001496 PMID: 28708810

14. Guaraldi G. et al., “Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV,” *AIDS*, vol. 35, no. 6, pp. 939–945, 2021, https://doi.org/10.1097/QAD.00000000000002853 PMID: 28708810

15. Cento V. and Perno C. F., “Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naive, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety,” *J. Glob. Antimicrob. Resist.*, vol. 20, pp. 228–237, 2020, https://doi.org/10.1016/j.jgar.2019.08.010 PMID: 31446092

16. De Francesco M. A. et al., “Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naïve and -Experienced HIV-1 Infected Patients: A Single Center Experience,” *AIDS Res. Hum. Retroviruses*, vol. 34, no. 7, pp. 570–574, 2018, https://doi.org/10.1089/aid.2018.0006 PMID: 29631420

17. Guaraldi G., Milic J., Marcotullio S., and Mussini C., “A patient-centred approach to deprescribing antiretroviral therapy in people living with HIV,” *J. Antimicrob. Chemother.*, pp. 1–6, 2020, https://doi.org/10.1093/jac/dkz325 PMID: 31369087

18. Back D. and Marzolini C., “The challenge of HIV treatment in an era of polypharmacy,” *JIAS*, vol. 23, p. e25449, 2020, https://doi.org/10.1002/jia2.25449/full